Neuren Pharmaceuticals

Perfil de la empresa

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.

Descripción disponible en inglés.

Datos societarios

Sector

Salud

Industria

Biotechnology

País

Australia

Sede

117 Camberwell Road, 3123, Hawthorn East

Cotización

NEU · ASX

Índices

S&P/ASX 200

Divisa

AUD

ISIN

NZNEUE0001S8

Sitio web

neurenpharma.com